Novartis AG ADR (NVS)
NYSE · Healthcare · Drug Manufacturers - General
Novartis AG ADR is a Healthcare company with a market capitalization of $296.54B, a trailing P/E ratio of 22.3, and a dividend yield of 3.05%.
5-Year Price History
Latest Annual Financials · FY ending December 31, 2025
Recent Quarterly Earnings (EPS)
| Quarter | Reported | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| Q1 2026 | April 28, 2026 | $1.65 | $1.65 | +0.0% |
| Q4 2025 | February 4, 2026 | $2.03 | $2.00 | +1.5% |
| Q3 2025 | October 28, 2025 | $2.25 | $2.31 | -2.6% |
| Q2 2025 | July 17, 2025 | $2.42 | $2.37 | +2.1% |
| Q1 2025 | April 29, 2025 | $2.28 | $2.17 | +5.1% |
| Q4 2024 | January 31, 2025 | $1.98 | $1.76 | +12.5% |
Other Drug Manufacturers - General Stocks
Frequently Asked Questions
What is Novartis AG ADR's market cap?
As of June 29, 2026, Novartis AG ADR (NVS) has a market capitalization of $296.54B.
What is Novartis AG ADR's P/E ratio?
Novartis AG ADR trades at a trailing price-to-earnings (P/E) ratio of 22.3. Its forward P/E is 17.6.
Does Novartis AG ADR pay a dividend?
Yes — Novartis AG ADR pays a dividend yielding 3.05%, an annual payout of $4.67 per share.
What sector is NVS in?
Novartis AG ADR is in the Healthcare sector, specifically the Drug Manufacturers - General industry.
What was Novartis AG ADR's revenue?
In its latest reported fiscal year (ending December 31, 2025), Novartis AG ADR reported revenue of $54.81B and net income of $14.06B.
Ask your own questions about NVS
Try mrmarket.ai freeData as of June 29, 2026. Figures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.